Develops drugs for metabolic dysfunction-associated steatohepatitis.
Jun 2026Revenue $1.28B/yrExpenses $1.61B/yr
No trendCash runway ≈ 4.1 years from Jun 2026
Figures by year
When will Madrigal Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $1.28B and expenses $1.61B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $958M | $1.26B | −$300M |
| Dec 2024 | $180M | $678M | −$498M |
| Dec 2023 | $0.00 | $380M | −$380M |
| Dec 2022 | $0.00 | $294M | −$294M |
| Dec 2021 | $0.00 | $242M | −$242M |
| Dec 2020 | $0.00 | $207M | −$207M |
| Dec 2019 | $0.00 | $95.0M | −$95.0M |
| Dec 2018 | $0.00 | $40.7M | −$40.7M |
| Dec 2017 | $0.00 | $32.1M | −$32.1M |
| Dec 2012 | $147K | $61.1M | −$60.9M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.